Myeloproliferative Disorders Treatment Market Outlook:
Myeloproliferative Disorders Treatment Market size was valued at USD 6.9 billion in 2024 and is estimated to reach USD 15.5 billion by the end of 2037, exhibiting a CAGR of 7.6% during the forecast period, i.e., 2025-2037. In 2025, the industry size of myeloproliferative disorders treatment is assessed at USD 7.5 billion.
According to the report of the National Institute of Health, myeloproliferative disorder is diagnosed among approximately 350,000 patients annually worldwide. Polycythemia and myelofibrosis are the most common traits within the diagnosed patient as per medical evaluation. The aging population is vulnerable to health risks due to myeloproliferative disorders. Demographic switch and growth in the aged population are expected to leverage the demand for myeloproliferative disorders treatment in the global market. Government support in the elevation of myeloproliferative disorders treatment is considerably high, which ensured better infrastructure and R&D for better patient outcomes. The inclusion of personalized medicine advancements like AI-driven drug directed to reduce the trial time and enhance the treatment procedure throughout the world.
Furthermore, active pharmaceutical ingredients (APIs) are the primary raw material that is required for myeloproliferative disorders therapy. Europe and North America are the dominant markets in the production of JAK inhibitor API, whereas hydroxyurea is predominantly supplied from India and China. According to the data published by the U.S. Bureau of Labor Statistics, the producer price index for MPD drugs rose by 4.3% and the consumer price index for treatments increased by 7.2%. The high market demand resulted a rise in API price and cost of the therapy in the global market. According to the reporting of the National Health Institute, approximately USD 2.9 billion is invested in research, development, and deployment in the myeloproliferative disorders, and 76% of clinical trials are for JAK inhibitors and gene therapy.
Myeloproliferative Disorders Treatment Market - Growth Drivers and Challenges
Growth Drivers
- Early intervention in healthcare: An increased awareness and improvement in the health diagnosis infrastructure, directed growth in early diagnosis practice in myeloproliferative disorders. According to the study of the Food and Drug Administration, hospitalization cases are reduced by approximately 30% through the use of JAK inhibitors. This enables the U.S. healthcare to save an amount of USD 440 million within two years. The survival rate for five years within myelofibrosis patients has risen to approximately 19% with the initiative of Germany’s disease management programs. Long-term cost is controlled through the emerging trend of the value-based care model that advocates prophylactic MPD treatment for patients.
- Pharmaceutical innovation: New and efficient pharmaceutical solutions for myeloproliferative disorders deliver better patient outcomes. For instance, Novartis has launched a Phase III myelofibrosis drug in 2025 that provides a targeted therapy for the CALR mutation. The successful outcome of the drug resulted in the accumulation of 16% market share. According to the report of the National Institute of Health, gene editing therapy that is based on CRISPR is being introduced for trials that are anticipated to be applicable for CML resistance and management in myeloproliferative disorders. Innovation and research are making the myeloproliferative disorders treatment market more potential to elevate the patient outcome factors and experience robust growth.
Manufacturing Strategies to Ensure Myeloproliferative Disorders Treatment Market Expansion
Implications of key strategies such as precision medicine, geographic expansion, and pricing strategies, directed the manufacturer to expand its business on a global platform. For instance, Novartis accumulated 19% of the myeloproliferative disorders treatment market in U.S. myeloproliferative disorders treatment with the introduction of targeted CALR-mutant therapy. On the contrary, the expansion of reimbursement rate by Incyte, more than USD 400 million, is achieved by the company. Th expanded business in Asia Pacific and alignment with the local demand elevated the revenue accumulation rate by more than 30% for Bristol-Myers. According to the report of the National Institute of Health, domestic production of TKI reduces the cost of production and enables offering an affordable rate of treatment to the market.
Revenue Growth Opportunities (2023-2025)
|
Company |
Strategy Implemented |
Projected Revenue Impact (USD) |
Implementation Year |
|---|---|---|---|
|
Novartis |
CALR+ myelofibrosis drug (2023) |
+585 million |
2023 |
|
Incyte |
Introduction of CMS-backed combo therapy (2024) |
+422 million |
2024 |
|
Bristol-Myers Squibb |
Aligning with the market demand of India/China generics (2025) |
+315 million |
2025 |
|
Pfizer |
Investment in Ruxolitinib biosimilar |
+1.2 billion |
2025 |
Key Market Dynamics for Historical Patient Growth
The myeloproliferative disorders treatment market gained a fundamental shape from 2010 to 2020. The key factors that lead to dynamic growth in the myeloproliferative disorders treatment market include drug development, reimbursement and pricing model, and market potential within the emerging regions. For instance, research and development investment elevated in the U.S. within the JAK inhibitors that leveraged the patient growth within the concerned market. Patient volume increased in Germany through the expansion of the medical coverage limit and increased accessibility of the concerned market. Low-cost generics are the unmet demand in the myeloproliferative disorders treatment market of India, aligning with the myeloproliferative disorders treatment market requirement, more than 90% of patient growth is experienced in the addressed market.
Historical MPD Patient Growth (2010-2020)
|
Country |
2010 Procedures (millions) |
2020 Procedures (millions) |
CAGR (%) |
|
U.S. |
46 |
69 |
4.4% |
|
Germany |
13 |
23 |
6.5% |
|
France |
10 |
17 |
6.5% |
|
Spain |
6.5 |
11.3 |
6.7% |
|
Australia |
3.2 |
6.4 |
7.4% |
|
Japan |
18.8 |
28.6 |
4.8% |
|
India |
8.8 |
15.3 |
6.9% |
|
China |
25.1 |
48.9 |
7.3% |
Challenge
- Delay in approval: The time required to receive clearance before launching a drug in the myeloproliferative disorders treatment market is an influential factor that impacts the treatment progress. Complex and long-time-consuming procedures for clinical trials often lead to high delays in achieving regulatory approval and launching the product in the concerned market. For instance, the Pharmaceuticals and Medical Devices Agency in Japan took six months additional to provide clearance for Incyte's pemigatinib in 2022. This resulted in high delays in product launch and led to bear loss and market constraints for the business. The same barrier is also experienced in Europe because of the implementation of the Orphan Drug Process, which incorporates eighteen to twenty-four months to receive clearance.
Myeloproliferative Disorders Treatment Market Size and Forecast:
| Report Attribute | Details |
|---|---|
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
7.6% |
|
Base Year Market Size (2024) |
USD 6.9 billion |
|
Forecast Year Market Size (2037) |
USD 15.5 billion |
|
Regional Scope |
|
Myeloproliferative Disorders Treatment Market Segmentation:
Distribution Channel Segment Analysis
Based on the distribution channel, the hospital pharmacies segment possesses strong performance and is expected to accumulate a market share of 52.5% by 2037. The aspect of close monitoring and a higher level of infrastructure availability are required for JAK inhibitors and other treatments for myeloproliferative disorders. Dependency on the hospital pharmacies is higher due to the availability of advanced infrastructure and management capacities for side effects during treatments. Switching to myeloproliferative disorders treatment towards the targeted therapy and biologics is costly and dependent on the cold chain. Hospital pharmacists are equipped with the facility of providing Medicare support, stringent handling, and storage requirement that leads to higher access for patients to the concerned distribution channel.
Therapy Segment Analysis
In terms of therapy, the targeted therapy segment is anticipated to accumulate a myeloproliferative disorders treatment market share of 46% market share in 2037. The ability to address the target molecular mechanism and exert efficient control on the health risk symptoms resulted in better patient outcomes. Medical coverage for the patient is raised, which enables higher accessibility. Improved quality and standards successfully achieved patient reliance, which created high demand for targeted therapy in the global market.
Our in-depth analysis of the global myeloproliferative disorders treatment market includes the following segments:
|
Segment |
Subsegment |
|
Type |
|
|
Therapy |
|
|
Distribution Channel |
|
Vishnu Nair
Head - Global Business DevelopmentCustomize this report to your requirements — connect with our consultant for personalized insights and options.
Myeloproliferative Disorders Treatment Market - Regional Analysis
North America Market Insights
North America is the dominant region in the myeloproliferative disorders treatment market and is anticipated to grow by 49.5% of global market share by 2037. The presence of advanced health care infrastructure elevates the treatment procedure for myeloproliferative disorders. The region possesses the strongest healthcare infrastructure, including oncology centers, hematology departments, and targeted therapy. Private as well as public schemes are offered for insurance coverage to raise patient access to targeted therapies and other treatment procedures. Diagnosis rate and awareness within the population of North America led to early intervention. According to the report of the National Institute of Health large number of clinical trials are performed for MPD-related drugs in the U.S., which allows early access in the concerned market.
The U.S. is expected to secure to leading position in North America with a regional share of 42.5% by 2037 in the myeloproliferative disorders’ treatment market. The expansion in Medicare raised accessibility in the myeloproliferative disorders treatment market. According to the Centers for Medicare & Medicaid Services, more than USD 2 billion is invested in JAK inhibitor treatment, which provides coverage of approximately 54% to the myelofibrosis patients. Better quality of treatment and strategic cost management ensured a raised demand and better market performance in the concerned market. According to the report of the National Institute of Health, research and development within myeloproliferative disorders’ treatment is accelerated through investment of more than USD 640 billion. The accessibility rate of the patient is elevated through telemedicine adoption, which escalated patient participation by 27.5% after the pandemic period.
Asia Pacific Market Insights
Asia Pacific is anticipated to acquire a global market share of 18.5% in 2037 and is considered to be the emerging region in the myeloproliferative disorder treatment market. The aging population and increased awareness related to early diagnosis have increased the incidence of myeloproliferative disorders. Lifestyle issues such as obesity, smoking, and many more are addressed as the key factors that have raised the incidence of myeloproliferative disorders in the Asia Pacific. Robust investment is conducted to elevate the health infrastructure in India, China, and many other countries. Affordable treatment and digital integration are the key drivers for market demand growth for myeloproliferative disorders treatment. Insurance expansion through schemes, including Ayushman Bharat in India, Japan’s universal healthcare system, and many more, has advocated for the adoption of innovation in myeloproliferative disorders treatment.
The myeloproliferative disorders treatment market in China is dominating the Asia Pacific region. The implementation of fast-track approval as per the direction of the National Medical Products Administration is a leading growth driver for the addressed market. The availability of fast clearance resulted in higher market penetration, and elevation of the treatment procedure enhanced market demand for myeloproliferative disorders treatment. More than USD 2 billion is spent annually to enhance blood cancer therapy in China to improve patient outcomes. According to the report published by the National Health Commission of China, more than 1 million patients were diagnosed with myeloproliferative disorders in 2023. Therefore, a surge in thecases of myeloproliferative disorders led to the demand for advanced treatment and market growth.
Key Myeloproliferative Disorders Treatment Market Players:
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
A highly consolidated market is experienced by the business in the myeloproliferative disorders treatment market. Key strategies that delivered a competitive edge to the top players of the global market include precision medicine, biosimilar competition, emerging market expansion, and many more. Novartis invested in CALR/MPL mutation-targeted drugs that derived high market acceptance and better patient outcomes. Pfizer introduced a ruxolitinib biosimilar for clinical testing and to be launched in the myeloproliferative disorders treatment market by 2026 to fulfill the market demand in myeloproliferative disorders. Besides, collaborating with the government scheme allowed higher market penetration for Takeda in Japan. GSK also collaborated with the UK NICE to expand the reimbursement rate and gain better market accessibility. Meanwhile, patient retention is accelerated by 19% by Incyte with the help of telehealth integration.
Here is a list of key players operating in the global market:
|
Company Name |
Country of Origin |
Market Share (2024) |
Industry Focus |
|
Novartis AG |
Switzerland |
18.8% |
JAK inhibitors (Jakavi), CALR-targeted therapies |
|
Pfizer Inc. |
U.S. |
15.7% |
Ruxolitinib (Jakafi), biosimilars in development |
|
Bristol-Myers Squibb |
U.S. |
13.2% |
TKIs (Sprycel for CML), immunotherapy combos |
|
Incyte Corporation |
U.S. |
10.9% |
Fedratinib (Inrebic), MF-focused R&D |
|
Takeda Pharmaceutical |
Japan |
8.9% |
Momelotinib (Ojjaara), APAC market expansion |
|
GSK plc |
UK |
xx% |
Momelotinib (NDA 2023), EU/UK dominance |
|
Roche |
Switzerland |
xx% |
Diagnostics + targeted therapies (MF/PV) |
|
AstraZeneca |
UK |
xx% |
Rare disease pipeline (CALR+ MF candidates) |
|
Johnson & Johnson |
U.S. |
xx% |
Immunotherapy collaborations (CAR-T for MF) |
|
Merck KGaA |
Germany |
xx% |
BTK inhibitors, EU-centric distribution |
|
Sanofi |
France |
xx% |
Interferon-alpha therapies (PV/ET) |
|
AbbVie |
U.S. |
xx% |
Combo therapies (ruxolitinib + navitoclax) |
|
Daiichi Sankyo |
Japan |
xx% |
TKIs for CML, Japan market leader |
|
Daiichi Sankyo Company |
Japan |
xx% |
|
|
CSL Limited |
Australia |
xx% |
Plasma-derived therapies for MPN complications |
|
Celltrion |
South Korea |
xx% |
Biosimilar ruxolitinib (2025 launch) |
|
Dr. Reddy’s Laboratories |
India |
xx% |
Generics (hydroxyurea, anagrelide) for emerging markets |
|
Lupin Pharmaceuticals |
India |
xx% |
Affordable JAK inhibitors for India/APAC |
|
Biocon |
India |
xx% |
Biosimilars in partnership with Mylan |
|
Hikma Pharmaceuticals |
UK |
xx% |
MENA region distribution of generics |
|
Pharmaniaga |
Malaysia |
xx% |
Local manufacturing for Southeast Asia |
Below are the areas covered for each company in the myeloproliferative disorder treatment market:
Recent Developments
- In September 2024, GSK launched Momelotinib, which is considered to be the first JAK1/JAK2/ACVR1 inhibitor specifically approved for anemia-related myelofibrosis patients. More than 35% of the transfusion-dependent patients with anemia have benefited from the new product launch of the company.
- In January 2025, Novartis introduced CALR-mutant targeted therapy for 28% of the myelofibrosis patients diagnosed with CALR mutation scopes. This is considered to be the first CALR-specific drug to reduce spleen volume by 49% in clinical trials.
- Report ID: 3034
- Published Date: Jun 19, 2025
- Report Format: PDF, PPT
Have specific data needs or budget constraints?
Reach out to us for a customized quote or to learn more about our special pricing
for startups and universities
Frequently Asked Questions (FAQ)
Myeloproliferative Disorders Treatment Market Report Scope
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Connect with our Expert
